In general, the concept of biosimilar medicinal products is applicable to any biological drug. However, in practice, the designation of a product as a “biosimilar” depends on the ability to comprehensively characterize the substance, thereby establishing the comparability of the product in question.
The characterization of biosimilars is significantly more complex than that of small-molecule chemical drugs. This complexity is further exacerbated by the molecular intricacy inherent in diverse products such as recombinant DNA, blood and blood-derived products, immunologicals, and gene and cell therapies. Furthermore, parameters such as the tertiary structure of proteins and post-translational modifications (PTMs)—notably glycosylation profiles—can be extensively altered by what are considered minor changes in the manufacturing process. Consequently, the safety and efficacy profiles of these products are strictly contingent upon the robust control of quality attributes throughout the entire production lifecycle.
Biosimilars represent a new generation of biological medicines designed to be highly similar to an existing reference (originator) product, with no clinically meaningful differences in terms of safety, purity, and potency (efficacy). The utilization of these agents has increased substantially in recent years, as they facilitate patient access to advanced therapies at a lower cost.
Biosimilars are primarily employed in the management of chronic and complex diseases, including various malignancies, autoimmune disorders (such as rheumatoid arthritis and psoriasis), inflammatory bowel disease (IBD), and certain hematological disorders. In these therapeutic areas, the primary advantage of biosimilars is the reduction of healthcare expenditures without compromising clinical quality, enabling healthcare systems to extend biological treatment coverage to a larger patient population.
Biosimilars represent a new generation of biological medicines designed to be highly similar to an existing reference (originator) product, with no clinically meaningful differences in terms of safety, purity, and potency (efficacy). The utilization of these agents has increased substantially in recent years, as they facilitate patient access to advanced therapies at a lower cost.
Biosimilars are primarily employed in the management of chronic and complex diseases, including various malignancies, autoimmune disorders (such as rheumatoid arthritis and psoriasis), inflammatory bowel disease (IBD), and certain hematological disorders. In these therapeutic areas, the primary advantage of biosimilars is the reduction of healthcare expenditures without compromising clinical quality, enabling healthcare systems to extend biological treatment coverage to a larger patient population.
Due to their complex and sensitive biological nature, biosimilars are categorized among medicinal products that demand rigorous quality and safety mandates regarding their manufacturing, analysis, and storage. Even minute deviations in the production process can significantly impact the structural integrity and clinical efficacy of these drugs. Consequently, the implementation of advanced instrumentation, isolated production lines, and robust contamination control systems is imperative.
In modern biosimilar manufacturing units, classified cleanrooms, fully automated mechanized washing and sterilization systems, and stringent protocols are employed to prevent any contact between personnel and pharmaceutical substances. This infrastructure not only ensures product quality and molecular stability but also guarantees the safety of the workforce and the environment. Such facilities enable the production of diverse dosage forms—including vials, pre-filled syringes (PFS), and lyophilized (freeze-dried) products—in full compliance with current Good Manufacturing Practices (cGMP) and international standards.
